文献速递神经肿瘤

自体树突状细胞免疫治疗在恶性胶质瘤综合治疗中的结果

Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas - results.
PubMed 文献 · J Neurooncol · 2024-01-16

单中心前瞻性队列研究纳入91例经组织学确诊的恶性胶质瘤(胶质母细胞瘤)患者,比较标准治疗联合自体树突状细胞疫苗与单纯标准治疗的疗效。免疫治疗组41例,对照组50例。免疫治疗组中位生存期21.7个月(95%CI 4-37个月),对照组15.8个月(95%CI 3-22个月)(p=0.002);中位无复发生存期分别为13.8个月(95%CI 1-20个月)和7.9个月(95%CI 1-12个月)(p=0.003)。

要点

  • 免疫治疗组中位生存期21.7个月(95%CI 4-37个月),对照组15.8个月(95%CI 3-22个月),p=0.002。
  • 免疫治疗组中位无复发生存期13.8个月(95%CI 1-20个月),对照组7.9个月(95%CI 1-12个月),p=0.003。
  • 作者认为免疫治疗在总生存期和无复发生存期方面显示出明确的积极趋势,但仍需进一步开发、研究和改进。

核心结论

  • 在恶性胶质瘤患者的综合治疗中应用免疫治疗,在总生存期和中位无复发生存期方面显示出明确的积极趋势。
  • 免疫治疗作为治疗工具仍需进一步开发、研究和改进,需考虑恶性胶质瘤中的免疫抑制及克服手段、靶抗原选择优化、细胞制备以及树突状疫苗与其他治疗方案的整合。

研究设计与样本

  • 单中心、前瞻性、队列研究,在俄罗斯A.L. Polenov神经外科研究所(RNSI named after prof. A.L. Polenov)开展。
  • 共纳入91例经组织学确诊的恶性胶质瘤(胶质母细胞瘤)患者;主组41例在标准治疗(手术、放疗和化疗)基础上接受特异性抗肿瘤免疫治疗,对照组50例仅接受标准治疗、未接受免疫治疗。

主要发现

  • 免疫治疗组中位生存期为21.7个月(95%CI 4-37个月),非免疫治疗组为15.8个月(95%CI 3-22个月)(p=0.002)。
  • 免疫治疗组中位无复发生存期为13.8个月(95%CI 1-20个月),非免疫治疗组为7.9个月(95%CI 1-12个月)(p=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ANNOTATION: Malignant gliomas are the most common primary brain tumor. Despite the variety of modern treatments, it is still a fatal disease with an extremely poor prognosis. The use of immunotherapy as a technique for the treatment of malignant tumors has great promise, retraining and exploiting the patient's immune response against tumors. OBJECTIVE: Evaluation of the effectiveness of dendritic cell vaccine in patients with malignant brain gliomas in the structure of complex treatment in comparison with the control group of patients without immunotherapy in the structure of treatment. MATERIALS AND METHODS: In a single-center, prospective, cohort study, taking place on the basis of the RNSI named after prof. A.L. Polenov, 91 patients with morphologically established malignant glial tumor (glioblastoma) took part. The main group of 41 patients who, in addition to standard treatment (surgical, radiation and chemotherapy), underwent specific antitumor immunotherapy. 50 patients received only standard treatment, without immunotherapy. RESULTS: Median survival was 21.7 months in the immunotherapy group (95% CI 4-37 months) and 15.8 months (95% CI 3-22 months) in the non-immunotherapy group (p = 0.002). The median relapse-free period in the group with immunotherapy was 13.8 months (95% CI 1-20 months), and in the group without immunotherapy 7.9 months (95% CI 1-12 months) (p = 0.003). CONCLUSION: In general, the use of immunotherapy in the structure of complex treatment of patients with malignant gliomas demonstrates a clear positive trend in terms of overall survival and median relapse-free period. But nevertheless, immunotherapy requires further development as a therapeutic tool, study and improvement, which will take into account immunosuppression in malignant gliomas and means of overcoming it, optimization in terms of target antigen selection, cell preparation and integration of dendritic vaccines into other treatment regimens.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Rynda AY, Rostovthev DM, Zabrodskaya YM, et al. Immunotherapy with autologous dendritic cells in the complex treatment of malignant gliomas - results. J Neurooncol. 2024. PMID: 38227144. doi:10.1007/s11060-023-04559-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。